160 related articles for article (PubMed ID: 34270987)
1. The involvement of epithelial-to-mesenchymal transition in doxorubicin resistance: Possible molecular targets.
Mirzaei S; Abadi AJ; Gholami MH; Hashemi F; Zabolian A; Hushmandi K; Zarrabi A; Entezari M; Aref AR; Khan H; Ashrafizadeh M; Samarghandian S
Eur J Pharmacol; 2021 Oct; 908():174344. PubMed ID: 34270987
[TBL] [Abstract][Full Text] [Related]
2. Lgr5-mediated p53 Repression through PDCD5 leads to doxorubicin resistance in Hepatocellular Carcinoma.
Ma Z; Guo D; Wang Q; Liu P; Xiao Y; Wu P; Wang Y; Chen B; Liu Z; Liu Q
Theranostics; 2019; 9(10):2967-2983. PubMed ID: 31244936
[TBL] [Abstract][Full Text] [Related]
3. Emodin: One Main Ingredient of Shufeng Jiedu Capsule Reverses Chemoresistance of Lung Cancer Cells Through Inhibition of EMT.
Ying Y; Qingwu L; Mingming X; Zhenju S; Chaoyang T; Zhengang T
Cell Physiol Biochem; 2017; 42(3):1063-1072. PubMed ID: 28662514
[TBL] [Abstract][Full Text] [Related]
4. Oleuropein inhibits migration ability through suppression of epithelial-mesenchymal transition and synergistically enhances doxorubicin-mediated apoptosis in MCF-7 cells.
Choupani J; Alivand MR; M Derakhshan S; Zaeifizadeh M; S Khaniani M
J Cell Physiol; 2019 Jun; 234(6):9093-9104. PubMed ID: 30317622
[TBL] [Abstract][Full Text] [Related]
5. MiR-451a attenuates doxorubicin resistance in lung cancer via suppressing epithelialmesenchymal transition (EMT) through targeting c-Myc.
Tao L; Shu-Ling W; Jing-Bo H; Ying Z; Rong H; Xiang-Qun L; Wen-Jie C; Lin-Fu Z
Biomed Pharmacother; 2020 May; 125():109962. PubMed ID: 32106373
[TBL] [Abstract][Full Text] [Related]
6. miR-137 alleviates doxorubicin resistance in breast cancer through inhibition of epithelial-mesenchymal transition by targeting DUSP4.
Du F; Yu L; Wu Y; Wang S; Yao J; Zheng X; Xie S; Zhang S; Lu X; Liu Y; Chen W
Cell Death Dis; 2019 Dec; 10(12):922. PubMed ID: 31801953
[TBL] [Abstract][Full Text] [Related]
7. The related miRNAs involved in doxorubicin resistance or sensitivity of various cancers: an update.
Torki Z; Ghavi D; Hashemi S; Rahmati Y; Rahmanpour D; Pornour M; Alivand MR
Cancer Chemother Pharmacol; 2021 Nov; 88(5):771-793. PubMed ID: 34510251
[TBL] [Abstract][Full Text] [Related]
8. Knockdown of TWIST enhances the cytotoxicity of chemotherapeutic drugs in doxorubicin-resistant HepG2 cells by suppressing MDR1 and EMT.
Li R; Wu C; Liang H; Zhao Y; Lin C; Zhang X; Ye C
Int J Oncol; 2018 Oct; 53(4):1763-1773. PubMed ID: 30066890
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-106b modulates epithelial-mesenchymal transition by targeting TWIST1 in invasive endometrial cancer cell lines.
Dong P; Kaneuchi M; Watari H; Sudo S; Sakuragi N
Mol Carcinog; 2014 May; 53(5):349-59. PubMed ID: 24002805
[TBL] [Abstract][Full Text] [Related]
10. Chemoresistance to doxorubicin induces epithelial-mesenchymal transition via upregulation of transforming growth factor β signaling in HCT116 colon cancer cells.
Li J; Liu H; Yu J; Yu H
Mol Med Rep; 2015 Jul; 12(1):192-8. PubMed ID: 25684678
[TBL] [Abstract][Full Text] [Related]
11. ZEB1 mediates doxorubicin (Dox) resistance and mesenchymal characteristics of hepatocarcinoma cells.
Long L; Xiang H; Liu J; Zhang Z; Sun L
Exp Mol Pathol; 2019 Feb; 106():116-122. PubMed ID: 30615851
[TBL] [Abstract][Full Text] [Related]
12. DUSP4 Silencing Enhances the Sensitivity of Breast Cancer Cells to Doxorubicin through the Activation of the JNK/c-Jun Signalling Pathway.
Al-Mutairi MS; Habashy HO
Molecules; 2022 Sep; 27(19):. PubMed ID: 36234680
[TBL] [Abstract][Full Text] [Related]
13. miR-300 inhibits epithelial to mesenchymal transition and metastasis by targeting Twist in human epithelial cancer.
Yu J; Xie F; Bao X; Chen W; Xu Q
Mol Cancer; 2014 May; 13():121. PubMed ID: 24885626
[TBL] [Abstract][Full Text] [Related]
14. NSC 74859 enhances doxorubicin cytotoxicity via inhibition of epithelial-mesenchymal transition in hepatocellular carcinoma cells.
Hu QD; Chen W; Yan TL; Ma T; Chen CL; Liang C; Zhang Q; Xia XF; Liu H; Zhi X; Zheng XX; Bai XL; Yu XZ; Liang TB
Cancer Lett; 2012 Dec; 325(2):207-13. PubMed ID: 22781398
[TBL] [Abstract][Full Text] [Related]
15. Molecular features of doxorubicin-resistance development in colorectal cancer CX-1 cell line.
Kubiliūtė R; Šulskytė I; Daniūnaitė K; Daugelavičius R; Jarmalaitė S
Medicina (Kaunas); 2016; 52(5):298-306. PubMed ID: 27746118
[TBL] [Abstract][Full Text] [Related]
16. New insight towards development of paclitaxel and docetaxel resistance in cancer cells: EMT as a novel molecular mechanism and therapeutic possibilities.
Ashrafizadeh M; Mirzaei S; Hashemi F; Zarrabi A; Zabolian A; Saleki H; Sharifzadeh SO; Soleymani L; Daneshi S; Hushmandi K; Khan H; Kumar AP; Aref AR; Samarghandian S
Biomed Pharmacother; 2021 Sep; 141():111824. PubMed ID: 34175815
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of chemotherapy-related breast tumor EMT by application of redox-sensitive siRNA delivery system CSO-ss-SA/siRNA along with doxorubicin treatment.
Liu X; Zhou XQ; Shang XW; Wang L; Li Y; Yuan H; Hu FQ
J Zhejiang Univ Sci B; 2020 Mar; 21(3):218-233. PubMed ID: 32133799
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of Heat Shock Protein 90 suppresses TWIST1 Transcription.
Chong KY; Kang M; Garofalo F; Ueno D; Liang H; Cady S; Madarikan O; Pitruzzello N; Tsai CH; Hartwich TMP; Shuch BM; Yang-Hartwich Y
Mol Pharmacol; 2019 Aug; 96(2):168-179. PubMed ID: 31175180
[TBL] [Abstract][Full Text] [Related]
19. Overcoming doxorubicin resistance in cancer: siRNA-loaded nanoarchitectures for cancer gene therapy.
Paskeh MDA; Saebfar H; Mahabady MK; Orouei S; Hushmandi K; Entezari M; Hashemi M; Aref AR; Hamblin MR; Ang HL; Kumar AP; Zarrabi A; Samarghandian S
Life Sci; 2022 Jun; 298():120463. PubMed ID: 35259354
[TBL] [Abstract][Full Text] [Related]
20. Cx32 reverses epithelial-mesenchymal transition in doxorubicin-resistant hepatocellular carcinoma.
Yu M; Han G; Qi B; Wu X
Oncol Rep; 2017 Apr; 37(4):2121-2128. PubMed ID: 28260043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
